|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
With the notable exception of ALK-pos anaplastic large cell lymphoma (ALCL), the prognosis of most PTCL subtypes is extremely is poor with a 5 y overall survival of approximately 15-30% in most series.
|
17512649 |
2007 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
With the exception of ALK-positive anaplastic large cell lymphoma (ALCL), which is defined on the basis of ALK rearrangements, genetic features play little role in the definition of other disease entities.
|
22160055 |
2011 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
With notable exceptions such as ALK(+) anaplastic large cell lymphoma (ALCL, ALK+), the molecular abnormalities in PTCL remain poorly characterised.
|
21887344 |
2011 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
While the cause-effect relationship between ALK fusions and malignancies such as ALCL and IMT is very well established, more circumstantial links implicate the involvement of the full-length, normal ALK receptor in the genesis of additional malignancies including glioblastoma, neuroblastoma, breast cancer, and others; in these instances, ALK is believed to foster tumorigenesis following activation by autocrine and/or paracrine growth loops involving the reported ALK ligands, pleiotrophin (PTN) and midkine (MK).
|
17694547 |
2008 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
While ALK-positive ALCL cells are sensitive to the Hsp90 inhibitor and the geldanamycin (GA) analog, 17-allylamino-17-demethoxygeldanamycin (17-AAG), the proteomic effects of these drugs on ALK-positive ALCL cells are unpublished.
|
17610208 |
2007 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
When OTX015 was associated with GANT61, a selective GLI1/2 inhibitor, C1156Y-resistant ALK ALCL growth was impaired.These findings support OTX015 clinical trials in refractory ALCL in combination with inhibitors of interleukin-2-inducible kinase or SHH/GLI1.
|
27793034 |
2016 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We used overlapping peptide microarray technology to analyze epitope-binding to NPM-ALK by plasma or serum from 129 ALK-positive ALCL patients and 21 controls.
|
30077013 |
2018 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We studied 24 anaplastic large cell lymphomas (ALCL) classified by World Health Organization criteria [17 primary nodal/systemic (10 ALK+, 7 ALK-), seven primary cutaneous], and 17 additional non-Hodgkin's lymphomas [one ALK+ B-lineage lymphoma, 14 ALK- diffuse large B-cell lymphomas (seven anaplastic variants, five nonanaplastic, two secondary CD30+), two follicular lymphomas].
|
15475930 |
2005 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We show for the first time that a small subset of cells purified from human anaplastic lymphoma kinase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary patient tumours using the side population (SP) technique have serial tumour-propagating capacity both in vitro and in vivo; they give rise to both themselves and the bulk tumour population as well as supporting growth of the latter through the production of soluble factors.
|
24814516 |
2015 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We report that NPM-ALK, the initiating oncogene of anaplastic large cell lymphomas (ALCLs), induces DNA damage and irreversibly arrests the cell cycle of primary fibroblasts and hematopoietic progenitors.
|
21518927 |
2011 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We report a case of systemic T-cell anaplastic large cell lymphoma CD30+ ALK- with CNS involvement at the time of diagnosis and unusual MRI characteristics resembling acute disseminated encephalomyelitis.
|
28427693 |
2017 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines.
|
29660984 |
2018 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We present an extensive catalog of proteins expressed by NPM/ALK-positive ALCL.
|
17560012 |
2007 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We present a case of anaplastic lymphoma kinase (ALK)+ skin-limited ALCL that highlights this challenge and draws attention to pitfalls in assessing ALK status.
|
25404214 |
2015 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We present a case describing a previously healthy 48 year-old female diagnosed with ALK-negative ALCL who achieved complete response with upfront single agent brentuximab-vedotin.
|
26809026 |
2016 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated Rb protein expression, both total (phosphorylated and underphosphorylated) and active (underphosphorylated), in four anaplastic lymphoma kinase (ALK)-positive ALCL cell lines (Karpas 299, JB-6, SU-DHL1, and SR-786) by Western blot analysis, and in 67 ALCL tumors (30 ALK-positive, 37 ALK-negative) using immunohistochemical methods.
|
15161658 |
2004 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have focused especially on ncRNAs that are regulated by the <i>NPM</i>-<i>ALK</i> fusion gene and illustrate how their deregulation contributes to the pathogenesis of ALCL.
|
31052302 |
2019 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We have developed a PCT methodology which has enabled the detection of the NPM-ALK rearrangements amongst seven t(2;5)(p23;q35) ALCL cases based on a long-range PCR of genomic DNA.
|
7772531 |
1995 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
We further evaluated the relationship between TIMP1 expression and STAT3 activation in 43 ALCL tumors (19 ALK(+) and 24 ALK(-)) using immunohistochemistry and a tissue microarray.
|
15161657 |
2004 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that NPM-ALK was able to bind Shp2 in coprecipitation experiments and to induce its phosphorylation in the tyrosine residues Y542 and Y580 both in HEK293 cells and ALCL cell lines.
|
17483340 |
2007 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that in ALK-rearranged ALCL cell lines, NPM-ALK was distributed in equal amounts between the cytoplasm and the nucleus.
|
26657151 |
2016 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the presence, extent, and prognostic impact of circulating tumor cells in bone marrow (BM) and peripheral blood (PB) of children and adolescents with NPM-ALK-positive ALCL at diagnosis using qualitative and quantitative polymerase chain reaction (PCR) for NPM-ALK.
|
17392503 |
2007 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the incidence of ALCL, clinical characteristics, survival status, and outcome of crizotinib use in four relapsed/refractory ALK-positive patients.
|
29150811 |
2018 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the anti-proliferative effects of everolimus and/or crizotinib in ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1, and lung adenocarcinoma cell line, NCI-H2228.
|
28675026 |
2018 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We concluded that Treg phenotype may be rarely seen in HTLV1-negative cases, such as PTCL, NOS and ALK-negative ALCL.
|
29898383 |
2018 |